Sage Therapeutics, Inc.
Funding rounds
2 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Dec 2020 | $650 M | Amount not plausible as filed | $250 million to $1 billion | equity | SEC | |
| Mar 2014 | $38 M | No. 2 | $10 to $50 million | equity | SEC | |
| Jan 2014 | $10 M | No. 1 | $10 to $50 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Sage Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Jan 2021).
SEC Form D · Jan 2021
The industry group it chose in its notices: Other Health Care.
SEC Form D · Jan 2021
That is all the official record says: Sage Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
6 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Arch Venture Fund VII LP | Venture capital | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| ARCH Venture Partners VII, LLC | Venture capital | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| ARCH Venture Partners VII, L.P. | Venture capital | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Third Rock Ventures GP II, L.P. | Venture capital | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Third Rock Ventures II, L.P. | Venture capital | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| TRV GP II, LLC | Other | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 15 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Albert J. Robichaud | Executive officer | Jan 2021 |
| Anne Marie Cook | Executive officer | Jan 2021 |
| Barry Greene | Executive officer | Jan 2021 |
| Jeffrey M. Jonas | Executive officer | Jan 2021 |
| Kimi Iguchi | Executive officer | Jan 2021 |
| Michael Cloonan | Executive officer | Jan 2021 |
| Stephen J. Kanes | Executive officer | Jan 2021 |
| Jeffery M. Jonas | Executive officer | Mar 2014 |
| Kimi M. Iguchi | Executive officer | Mar 2014 |
| Barry Greene | Director | Jan 2021 |
| Elizabeth F. Barrett | Director | Jan 2021 |
| Geno F. Germano | Director | Jan 2021 |
| George F. Golumbeski | Director | Jan 2021 |
| James F. Frates | Director | Jan 2021 |
| Jeffrey M. Jonas | Director | Jan 2021 |
| Kevin P. Starr | Director | Jan 2021 |
| Michael F. Cola | Director | Jan 2021 |
| Steven F. Paul | Director | Jan 2021 |
| Jeffery M. Jonas | Director | Mar 2014 |
| Kevin T. Starr | Director | Mar 2014 |
| Robert T. Nelsen | Director | Mar 2014 |
| Steven T. Paul | Director | Mar 2014 |